Clinical trial
A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation
NCT00136903 is registered in ClinicalTrials.gov with Mesoblast, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation
- Lead sponsor
- Mesoblast, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 27, 2005
- Completion date
- July 14, 2008
- Enrollment
- 32 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.